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There are often discrepancies when using different methods to measure anti-Toxoplasma
gondii IgG levels in patient samples. The diagnostic performance of a chemiluminescent
immunoassay (CLIA) and an enzyme-linked ﬂuorescent assay (ELFA) used as conﬁrma-
tory tests for samples identiﬁed as positive or equivocal by an electrochemiluminescent
immunoassay (ECLIA) were examined. Cut-off values were those stated by the manufac-
turer, andWestern blotwas used to conﬁrm the results of allmethods. All samples identiﬁed
as positive by ECLIA (n=93) were conﬁrmed as positive by Western blot, as were 14 of the 28
samples identiﬁed as equivocal. When these 121 samples were retested, the sensitivities of
CLIA and ELFA were 64.4% and 73.8%, respectively. Both methods exhibited a speciﬁcity ofELFA 100%. This study conﬁrms that the results obtained from the different immunoassays are
not comparable, and neither CLIA nor ELFA should be used to conﬁrm ECLIA results, which
should instead be conﬁrmed by methods such as Western blot or Sabin-Feldman dye test.
the different automated assays has recently been reported;
© 2012 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDInfection with Toxoplasma gondii is very common: previous
studies report infection rates of 49% to 71% in Brazilian
women,1,2 and 44% in French women of childbearing age.3
Toxoplasmosis exhibits a wide spectrum of clinical presenta-
tion ranging from asymptomatic to the severe forms observed
in fetal infections and in immunosuppressed patients.4 The
Sabin-Feldman dye test is considered the diagnostic gold
standard for the detection of toxoplasmosis, but its use is
complicated by the need for live parasites. Diagnostic results
obtained by Western blot show excellent correlation with
the Sabin-Feldman dye test: the presence of a 30 kDa band
in combination with at least two other bands at 31, 33, 40,
or 45 kDa are indicative of samples containing anti-T. gondii
IgG.5 Automated testing methods, such as enzyme-linked
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Este é um artigo Open Access sob a licençaﬂuorescent assay (ELFA), chemiluminescent immunoassay
(CLIA), and electrochemiluminescent immunoassay (ECLIA),
are oftenpreferred for routine screening. These assays identify
infection by detecting IgG antibodies speciﬁc for the para-
site. Additional detection of IgM antibodies can be used to
differentiate whether infection has occurred recently or not,
although the persistence of IgM for several months can neces-
sitate the use of IgG avidity testing in order to determine time
of infection.6
A low correlation between equivocal results obtained using825, Funcionários, Belo Horizonte, MG, 30110-021, Brazil.
it is suggested to be due to a lack of standardization in the
antigens used.7 The authors have also previously observed a
low correlation between assays regarding equivocal results.
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Table 1 – Diagnostic performance of alternative immunoassays used to conﬁrm anti-T. gondii IgG results from ECLIA
testing of patient serum samples.
Assay Result Total Western blot results Sensitivity* Speciﬁcity*
Positive Negative
ECLIA Positive 93 93 0 N/A N/A
Equivocal 28 14 14
Negative N/A N/A N/A
CLIA Positive 63 63 0 64.4% 100.0%
Equivocal 6 6 0
Negative 52 38 14
ELFA Positive 61 61 0 73.8% 100.0%
Equivocal 18 18 0
Negative 42 28 14
∗ Equivocal resultswere considered as positive results for the calculation of sensitivity and speciﬁcity. Themanufacturers’ recommended cut-off
values were used: ECLIA (negative, < 1 IU/mL; equivocal, ≥ 1 IU/mL and ≤ 30 IU/mL; positive, > 30 IU/mL); CLIA (negative, < 7.2 IU/mL; equivocal,
≥ 7.2 IU/mL and<8.8 IU/mL; positive, ≥ 8.8 IU/mL); ELFA (negative, < 4 IU/mL; equivocal, ≥ 4 IU/mL and<8 IU/mL; positive, ≥ 8 IU/mL). There
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rwere no equivocal results from Western blot. N/A, not applicable.
he aim of the present study was to evaluate the performance
f CLIA and ELFA in the conﬁrmation of results obtained by
CLIA.
Serum samples sent to the Division of Immunology of
he Instituto Hermes Pardini in Belo Horizonte, Brazil, were
nalyzed using the MODULAR® ECLIA (Roche Diagnostics –
annheim, Germany). A total of 121 samples identiﬁed as pos-
tive or equivocal (combined anti-T. gondii IgG titer > 1 IU/mL)
ere subsequently analyzed using two different automated
ssays: CLIA (LIAISON®, DiaSorin - Saluggia, Italy) and ELFA
VIDAS®, bioMérieux – Marcy-l’Étoile, France). In addition, all
amples were cryopreserved below− 20 ◦C for one month and
ent to the Laboratoire de Parasitologie in Marseille, France,
or conﬁrmatory testing by Western blot (LDBIO TOXO II IgG,
DBIO DIAGNOSTICS – Lyon, France). All assays (including cut-
ff values) were performed according to the manufacturer’s
peciﬁcations; equivocal results were considered positive for
he purpose of calculating assay sensitivities and speciﬁcities.
o clinical or socio-demographic characteristics of patients
ere obtained.
All samples identiﬁed as positive (n=93) by ECLIA were
onﬁrmed as positive by Western blot. Half of the 28 samples
dentiﬁed as equivocal by ECLIA were conﬁrmed as positive by
estern blot. Therefore, there were 107 true positive samples
n the 121 samples identiﬁed as either positive or equivocal by
CLIA (Table 1). When these 121 samples were retested using
he other assays, CLIA correctly identiﬁed 69 of the 107 positive
amples (sensitivity = 64.4%), and ELFA correctly identiﬁed 79
f the 107 positive samples (sensitivity = 73.8%). All true neg-
tive samples (samples tested negative by Western blot) were
dentiﬁed as negative by CLIA and ELFA, i.e. the speciﬁcity of
oth assays was 100%. All samples that had equivocal results
uring retesting by CLIA or ELFA were shown to be positive by
estern blot.
It is noteworthy that the high cut-off value used for a
ositive result recommended by the manufacturer of the
CLIA test is quite different from the other methods. This
ut-off value (≥30 IU/mL) proved appropriate for diagnostic
ccuracy in the present study, which conﬁrms the results
eported by Leslé et al.7 Western blot was positive in 50% ofsamples identiﬁed as equivocal by ECLIA, which is also in
agreement with the results of a previous study.7 In practice,
any equivocal IgG results should be retested, initially using
the same samples and then, if still equivocal, using fresh
samples taken within a few weeks of the initial sample.
Samples continuing to yield equivocal IgG results should be
tested by other methods, such as Western blot or the Sabin-
Feldman dye test. If equivocal results are obtained by ECLIA,
the use of other automated assays for conﬁrmation is not
appropriate, because their relatively low sensitivity may lead
clinicians to incorrectly consider many patients to be unin-
fected. ELFA iswidely used in Brazil and is often recommended
by laboratories as the most accurate test, even though ECLIA
has demonstrated and conﬁrmed higher sensitivity.5,8 Fur-
ther studies are clearly warranted in order to support this
recommendation.
Unfortunately, this study was not able to determine the
performance of tests in detecting seroconversion, as clinical
information of the patients was not obtained; however, the
superiority of Western blot for such determinations has been
reported.7 The results presented here cannot be applied to the
general population due to the small sample size and to the
absence of clinical data. Such generalization would require a
much larger clinical study involving additional markers, such
as IgM or IgG avidity, and other patient factors, such as co-
infections or pregnancy.
Serum anti-T. gondii IgG results obtained with differ-
ent automated assays are not comparable, despite the fact
that assays are standardized to World Health Organization’s
International Reference Standards. It is recommended that
serological monitoring be performed consistently using the
same manufacturer’s test, and that conﬁrmation of results
from ECLIA should rely on methods such as Western blot or
Sabin-Feldman dye test rather than on alternative automated
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